NCT06293950 Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
| NCT ID | NCT06293950 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Jordan |
| Condition | Autism |
| Study Type | INTERVENTIONAL |
| Enrollment | 14 participants |
| Start Date | 2022-03-09 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 14 participants in total. It began in 2022-03-09 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
Eligibility Criteria
Inclusion Criteria: * 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD Exclusion Criteria: * Age \> 14 years. * Patient weighing \< 10 kg. * History of severe Allergy * History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke. * Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past. * Evidence or history of severe, moderate, or uncontrolled systemic disease. * Inability to follow the prescribed dosing and follow-up schedule. * Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period. * Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study. * History of premature birth \<35 weeks' gestation. * Prior history of stroke in utero or other in utero insult.
Contact & Investigator
Abdallah Awidi, MD
STUDY DIRECTOR
Cell Therapy Center
Frequently Asked Questions
Who can join the NCT06293950 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 14 Years, studying Autism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06293950 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06293950 currently recruiting?
Yes, NCT06293950 is actively recruiting participants. Contact the research team at hanan.jafar@gmail.com for enrollment information.
Where is the NCT06293950 trial being conducted?
This trial is being conducted at Amman, Jordan.
Who is sponsoring the NCT06293950 clinical trial?
NCT06293950 is sponsored by University of Jordan. The principal investigator is Abdallah Awidi, MD at Cell Therapy Center. The trial plans to enroll 14 participants.